Advertisement

Topics

Teva Reports Positive Top-Line Data From Second Phase III Study Of SD-809

08:28 EDT 22 Sep 2016 | FinanzNachrichten

PETAH TIKVA (dpa-AFX) - Teva Pharmaceutical Industries Ltd. (TEVA) announced SD-809 (deutetrabenazine) showed statistically significant results in the second Phase III registration trial studying ...

Original Article: Teva Reports Positive Top-Line Data From Second Phase III Study Of SD-809

NEXT ARTICLE

More From BioPortfolio on "Teva Reports Positive Top-Line Data From Second Phase III Study Of SD-809"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...